Along with mismatch repair deficiency (dMMR), microsatellite instability (MSI) status and tumor mutational burden (TMB), PD-L1 has been identified as a potential predictive biomarker for endometrial cancer in some phase II clinical trials with immune checkpoint inhibitors [36, 37]. Here, CD274 is linked to neoplasm.